2025
Patient Satisfaction in the Headache Care at the Veterans Health Administration Headache Centers of Excellence: A Cross-Sectional Study
Kimber A, Fenton B, Zhou B, Anthony S, Sico J, Seng E. Patient Satisfaction in the Headache Care at the Veterans Health Administration Headache Centers of Excellence: A Cross-Sectional Study. Journal Of Patient Experience 2025, 12: 23743735251346615. PMID: 40520574, PMCID: PMC12163267, DOI: 10.1177/23743735251346615.Peer-Reviewed Original ResearchVeterans Health AdministrationVA Medical CenterHeadache careCross-sectional studyFacility patientsVeterans AffairsVeterans Health Administration SurveyVeterans Health Administration carePatient satisfactionPatient-centered careMedical CenterDeliver high-qualityHealthcare experiencesHeadache visitsCare SurveyHealth AdministrationImprove satisfactionCareCenters of excellenceVeteransProvidersAnalyzed responsesSatisfactionResponse rateHigh-qualityA phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses
Ettorre V, Bellone S, Greenman M, McNamara B, Palmieri L, Sethi N, Demirkiran C, Papatla K, Kailasam A, Siegel E, Ratner E, Santin A. A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses. Gynecologic Oncology 2025, 197: 110-115. PMID: 40334308, DOI: 10.1016/j.ygyno.2025.04.591.Peer-Reviewed Original ResearchProgression free survivalWhole-exome sequencingImmune checkpoint inhibitorsOverall survivalEndometrial cancerMicrosatellite instability-highCheckpoint inhibitorsFree survivalFollow-upResponse to immune checkpoint inhibitorsPatients treated with pembrolizumabProspective phase II studyExome sequencingResponse rateRecurrent platinum-resistantPhase II studyPhase 2 trialOverall survival dataEndometrial cancer patientsMLH-1MSI-H patientsFoundationOne platformImproved OSUpdate survivalPrognostic significancePhase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases.
Weiss S, Djureinovic D, Wei W, Tran T, Austin M, Markowitz J, Eroglu Z, Khushalani N, Hegde U, Cohen J, Sznol M, Anderson G, Johnson B, Piteo C, Mahajan A, Adeniran A, Jilaveanu L, Goldberg S, Chiang V, Forsyth P, Kluger H. Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases. Journal Of Clinical Oncology 2025, jco2402219. PMID: 40048689, DOI: 10.1200/jco-24-02219.Peer-Reviewed Original ResearchMelanoma brain metastasesOverall survivalBrain metastasesAnti-vascular endothelial growth factor therapyMedian intracranial progression-free survivalFour-year OS ratesIntracranial progression-free survivalResponse rateCirculating angiopoietin-2Median overall survivalTrial of pembrolizumabYears of pembrolizumabDose of bevacizumabProgression-free survivalPhase II trialGrowth factor therapyAdverse event ratesAssociated with responseOS ratesPD-1Radiation necrosisLocal therapyOn-therapyMetastatic tumorsFactor therapyEfficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer
Qi C, Shen L, Andre T, Chung H, Cannon T, Garralda E, Italiano A, Rieke D, Liu T, Burcoveanu D, Neu N, Mussi C, Xu R, Hong D, Drilon A, Berlin J. Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer. European Journal Of Cancer 2025, 220: 115338. PMID: 40068370, DOI: 10.1016/j.ejca.2025.115338.Peer-Reviewed Original ResearchTreatment-related adverse eventsSafety of larotrectinibMicrosatellite instability-highGI cancersMedian duration of responseNext-generation sequencing testMedian overall survivalProgression-free survivalDuration of responseNTRK gene fusionsOverall response rateFirst-in-classOverall survivalMedian durationTRK inhibitorsSolid tumorsTumor typesAdverse eventsExtended survivalLarotrectinibGastrointestinal cancerPatientsHepatic cancerResponse rateCancerQuick to connect: a comparison of virtual and in-person speed mentoring for emergency medicine medical students, residents by faculty at a national conference
Sun W, Goldflam K, Pennington Z, Derks L, Coates W, Nashu M, Hossin T, Clark A, Tsyrulnik A, Linden J. Quick to connect: a comparison of virtual and in-person speed mentoring for emergency medicine medical students, residents by faculty at a national conference. International Journal Of Emergency Medicine 2025, 18: 42. PMID: 40033204, PMCID: PMC11877889, DOI: 10.1186/s12245-025-00860-0.Peer-Reviewed Original ResearchSociety for Academic Emergency MedicineSpeed mentoringIn-personFree-text questionsAcademic Emergency MedicineResultsThe response rateIn-person mentoringModel of mentorshipExact testEmergency medicineThematic analysisMedical studentsViewpoints of participantsFischer's exact testMethodsMedical studentsParticipantsFaculty mentorsCOVID-19 pandemicProfessional growthResponse rateVirtual formatDatopotamab deruxtecan (Dato-DXd) in locally advanced/metastatic urothelial cancer: Updated results from the phase 1 TROPIONPanTumor01 study.
Meric-Bernstam F, Alhalabi O, Lisberg A, Drakaki A, Garmezy B, Kogawa T, Spira A, Salkeni M, Gao X, Tolcher A, Bhave M, Doroshow D, Hoffman-Censits J, Klauss G, Kaga Y, Kakurai Y, Kojima T. Datopotamab deruxtecan (Dato-DXd) in locally advanced/metastatic urothelial cancer: Updated results from the phase 1 TROPIONPanTumor01 study. Journal Of Clinical Oncology 2025, 43: 663-663. DOI: 10.1200/jco.2025.43.5_suppl.663.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsBlinded independent central reviewProgression-free survivalDuration of responsePartial responseIndependent central reviewComplete responseConfirmed ORRUrothelial cancerCentral reviewMedian duration of responseMedian progression-free survivalResponse rateImmune checkpoint inhibitorsInterstitial lung disease/pneumonitisTreatment-related AEsMedian follow-upSolid tumor typesAntibody-drug conjugatesPrimary study objectiveCheckpoint inhibitorsDose interruptionPretreated ptsStable diseaseData cutoffP3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell tumours (GCTs).
Mak B, Tran B, Thomas H, Pashankar F, Hansen A, Feldman D, Huddart R, Wheater M, Dunwoodie E, Mazhar D, Lawrence N, Stevanovic A, Birtle A, Oladipo O, Wyld D, Balagtas J, Stockler M, Grimison P. P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell tumours (GCTs). Journal Of Clinical Oncology 2025, 43: tps653-tps653. DOI: 10.1200/jco.2025.43.5_suppl.tps653.Peer-Reviewed Original ResearchMetastatic germ cell tumorsGerm cell tumorsProgression free survivalPhase 3 trialTwo-sided type I error rateRandomized trials of chemotherapyRandomized phase 3 trialIndependent data safety monitoring committeeData Safety Monitoring CommitteeResponse rateFirst-line chemotherapyStandard chemotherapy regimensFavorable response rateImprove cure ratesTrials of chemotherapyBaseline blood samplesSafety Monitoring CommitteePost-chemotherapy treatmentStage 1BEP chemotherapyStandard BEPTranslational substudyFree survivalChemotherapy regimensIntermediate-riskUpdated Adjustment of the HCAHPS Survey for New Modes of Survey Administration and Patient Mix.
Elliott M, Beckett M, Hambarsoomian K, Brown J, Cleary P, Lehrman W, Goldstein E, Giordano L, Parast L. Updated Adjustment of the HCAHPS Survey for New Modes of Survey Administration and Patient Mix. Medical Care 2025 PMID: 39878622, DOI: 10.1097/mlr.0000000000002127.Peer-Reviewed Original ResearchHCAHPS scoresPatient mixAssociated with more positive experiencesPositive patient experienceMeasure hospital performanceMode of survey administrationProtocol effectivenessSurvey response ratePatient-mix adjustmentHCAHPS surveyMail-onlyPatient experienceHospital performanceHCAHPSPlanned admissionsSurvey protocolSurvey administrationHospital admissionAdjusted modelsPositive experiencesHospitalResponse rateSurveyAdjustmentNegative adjustmentOutcomes in management of locally advanced rectal cancer with total neoadjuvant therapy in an underserved population.
Ganguly A, Paladiya R, Ingawale S, Giri S, Abbagoni V, Thumar J. Outcomes in management of locally advanced rectal cancer with total neoadjuvant therapy in an underserved population. Journal Of Clinical Oncology 2025, 43: 208-208. DOI: 10.1200/jco.2025.43.4_suppl.208.Peer-Reviewed Original ResearchTNT groupTotal neoadjuvant therapyLocally advanced rectal cancerAdvanced rectal cancerManagement of locally advanced rectal cancerTumor locationNeoadjuvant therapyConventional therapyRectal cancerCT groupPropensity score matchingLow tumorsHigh tumorNo responsePathologic response to treatmentTreating locally advanced rectal cancerResponse ratePartial response ratePathological response rateScore matchingFisher's exact testResponse to treatmentComplete responseAdjuvant treatmentUnderserved populationsCareer Choices for Graduates of Combined Medicine-Pediatrics Residency Programs: A Multi-year Survey
Agrawal A, Aronica M, Kisielewski M, Doolittle B. Career Choices for Graduates of Combined Medicine-Pediatrics Residency Programs: A Multi-year Survey. Journal Of General Internal Medicine 2025, 1-7. PMID: 39806250, DOI: 10.1007/s11606-024-09204-9.Peer-Reviewed Original ResearchMedicine-pediatricsPost-graduate yearCareer choiceAccreditation Council for Graduate Medical EducationResultsThe survey response rateResidency program graduatesAmerican Board of Internal MedicineAmerican BoardGraduate Medical EducationSurvey response rateAmerican Board of PediatricsHealthcare workforceMedical residentsSurvey yearAcademic yearAccreditation statusInternal medicineMedical educationTraining programPercentage of programsProgram graduatesResponse rateChief residentsPhysiciansAcademic practicePrioritizing attributes of approaches to analyzing patient-centered outcomes that are truncated due to death in critical care clinical trials: a Delphi study
Bahti M, Kahan B, Li F, Harhay M, Auriemma C. Prioritizing attributes of approaches to analyzing patient-centered outcomes that are truncated due to death in critical care clinical trials: a Delphi study. Trials 2025, 26: 15. PMID: 39794867, PMCID: PMC11721323, DOI: 10.1186/s13063-024-08673-x.Peer-Reviewed Original ResearchConceptsCritical care clinical trialsPatient-centerednessDelphi roundsConsensus thresholdModified Delphi processCritical care trialsPatient-centered outcomesInvited individualsCare trialsExperience expertsDelphi processDelphi panelDelphi studyClinical trialsResearch teamResponse rateResultsThirty-oneClinical relevancePersonal experienceTrialsRespondentsCritical attributesDeathOutcomesAnalysis approachWhat Are “Nonphysician Obligations” Anyway? A Survey Study Exploring Their Impact on Anesthesiology Resident Education and Developing a Conceptual Framework
Cormier N, Kinney D, Gaiser R. What Are “Nonphysician Obligations” Anyway? A Survey Study Exploring Their Impact on Anesthesiology Resident Education and Developing a Conceptual Framework. A&A Practice 2025, 19: e01885. PMID: 39745283, DOI: 10.1213/xaa.0000000000001885.Peer-Reviewed Original ResearchConceptsAnesthesiology traineesAccreditation Council for Graduate Medical EducationAllied health professionalsGraduate Medical EducationPatient-centeredHealth professionalsNurse anesthetistsClerical staffMedical educationNursesMedical specialtiesTrainee educationAcademic hospitalPatient transportAnesthesia techniciansResident educationGrounded theoryParticipants' responsesAnesthesiology residentsTraineesNonphysiciansAnesthesiologyConceptual frameworkResponse rateEducation
2024
Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
Foss F, Kim Y, Prince H, Akilov O, Querfeld C, Seminario-Vidal L, Fisher D, Kuzel T, Yannakou C, Geskin L, Feldman T, Sokol L, Allen P, Dang N, Cabanillas F, Wong H, Ooi C, Xing D, Sauter N, Singh P, Czuczman M, Duvic M. Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma. Journal Of Clinical Oncology 2024, 43: 1198-1209. PMID: 39700456, PMCID: PMC11949209, DOI: 10.1200/jco-24-01549.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaTreatment-emergent adverse eventsTime to responseT-cell lymphomaTumor burdenRefractory cutaneous T-cell lymphomaEnd pointsEfficacy end pointCapillary leak syndromePrimary efficacy analysisSecondary end pointsHuman interleukin-2Unmet medical needMedian DoRSystemic therapyInfusion reactionsOpen-labelDenileukin diftitoxEfficacy analysisAdverse eventsInterleukin-2Safety resultsQ1-Q3PatientsResponse ratePonatinib vs. asciminib in post–second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison
Garcia-Gutierrez V, Huang F, Ashaye A, Dalal M, Laliman-Khara V, Breccia M, Rutherford M, Moradian H, Patos P, Jabbour E. Ponatinib vs. asciminib in post–second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison. Frontiers In Oncology 2024, 14: 1455378. PMID: 39634261, PMCID: PMC11615674, DOI: 10.3389/fonc.2024.1455378.Peer-Reviewed Original ResearchMatching-adjusted indirect comparisonChronic-phase chronic myeloid leukemiaChronic myeloid leukemiaT315I mutationCP-CMLMyeloid leukemiaTyrosine kinase inhibitor therapyIndirect comparisonsResponse rateBaseline responsesSecond-generation TKIsT315I mutation statusKinase inhibitor therapyThird-line therapyMedical literature databasesInhibitor therapyMutation subgroupsMutation statusPatient-level dataEfficacy outcomesBaseline characteristicsMMR rateProportion Z testClinical trialsCumulative rateDeucravacitinib in Plaque Psoriasis: 4-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials
Armstrong A, Lebwohl M, Warren R, Sofen H, Morita A, Imafuku S, Ohtsuki M, Spelman L, Passeron T, Papp K, Colombo M, Vaile J, Vritzali E, Hoyt K, Daamen C, Banerjee S, Strober B, Thaçi D, Blauvelt A. Deucravacitinib in Plaque Psoriasis: 4-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. SKIN The Journal Of Cutaneous Medicine 2024, 8: s423. DOI: 10.25251/skin.8.supp.423.Peer-Reviewed Original ResearchAssess adverse eventsLong-term extensionModerate to severe plaque psoriasisExposure-adjusted incidence ratesSevere plaque psoriasisPlaque psoriasisLong-term extension trialsClinical response rateParent trialAdverse cardiovascular eventsTreatment of adultsSystemic therapyEfficacy outcomesHerpes zosterSafety profileVenous thromboembolismAdverse eventsDeucravacitinibEfficacy resultsCardiovascular eventsSafety signalsPatientsResponse rateIncidence ratePsoriasisThe longitudinal association between resilience and sleep quality in breast cancer
Li S, Mai Q, Mei X, Jiang Y, Xiong Y, Zeng Y, Knobf M, Ye Z. The longitudinal association between resilience and sleep quality in breast cancer. European Journal Of Oncology Nursing 2024, 74: 102734. PMID: 39571333, DOI: 10.1016/j.ejon.2024.102734.Peer-Reviewed Original ResearchDiagnosed breast cancerLongitudinal associationsSleep qualityPittsburgh Sleep Quality Index scaleBreast cancerCross-lagged panel modelBreast cancer programDiagnosed BC patientsCancer programsMissing itemsIndex scalePSQILatent growth modelingProtective factorsAssociated with changesResponse rateAssociationBC patientsBreastPatientsCancerMonthsQualityQuestionnaireResilienceLoncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers
Zelikson V, Gurumurthi A, Sawalha Y, Annunzio K, Saha A, Dong N, Qualls D, Amoozgar B, Kahl B, Baird J, Challa P, Huntington S, Santos J, Bair S, Narkhede M, Li S, Frosch Z, Ho C, Smith S, Winter A, Landsburg D, Furqan F, Hamadani M, Baird K, Romancik J, Alharthy H, Law J, Bojanini L, Advani R, Hu B, Johnson P, Grover N, Merril M, Crombie J, Shafagati N, Sterling C, Nastoupil L, Epperla N, Ayers E. Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers. Haematologica 2024, 110: 706-714. PMID: 39540227, PMCID: PMC11873705, DOI: 10.3324/haematol.2024.285977.Peer-Reviewed Original ResearchLOTIS-2Overall response rateOverall survivalAntibody drug conjugatesBulky diseaseComplete responseRefractory diffuse large B-cell lymphomaUS centersDiffuse large B-cell lymphomaLarge B-cell lymphomaEvaluate outcomes of patientsHigh riskResponse rateB-cell histologyR/R DLBCL patientsPre-treated patientsB-cell lymphomaOutcomes of patientsProportion of patientsRetrospective cohort studyCell of originDLBCL patientsReal-world settingsRetrospective studyReal-world analysisImpact of Self-Identified Race on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients Receiving Induction Therapy with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd)
Joseph N, Gupta S, Kaufman J, Dicamillo S, Roberts D, Gupta V, Hofmeister C, Dhodapkar M, Lonial S, Nooka A. Impact of Self-Identified Race on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients Receiving Induction Therapy with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd). Blood 2024, 144: 7870-7870. DOI: 10.1182/blood-2024-211988.Peer-Reviewed Original ResearchNewly diagnosed myelomaD-RVdBlack patientsStatistically significant differenceInduction therapyR-ISSOverall survivalMedian ageInternational Myeloma Working Group Uniform Response CriteriaWhite patientsImproved depth of responsePresence of extramedullary diseaseNewly diagnosed multiple myelomaResponse rateMedian overall survivalR-ISS-3Effective induction regimenHigh-risk featuresStem cell transplantationDepth of responseSignificant differenceClinical trial findingsStandard of careHigh-risk classificationMedian PFSSurvival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort
Braunstein Z, McLaughlin E, Lingamaneni P, Barta S, Cao M, Chang T, Ganesan N, Luu B, Mehta-Shah N, Shree T, Watkins M, Zain J, Allen P, Paulino D, Adams B, Wang J, Feng A, Marchi E, Roberts N, Wilcox R, Gutierrez M, Frosch Z, Sklarz T, Sethi T, Foss F, Beaven A, Haverkos B, Treitman R, Stevens P, Mishra A, Stuver R, Hampel P, Brammer J. Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort. Blood 2024, 144: 982-982. DOI: 10.1182/blood-2024-194242.Peer-Reviewed Original ResearchT-cell prolymphocytic leukemiaProgression-free survivalOverall survivalMedian OSFrontline treatmentT-PLL patientsTherapeutic outcomesMedian follow-up timeT-cell prolymphocytic leukemia cellsResponse rateCompared to CD4Multi-center seriesVenetoclax-based regimensSecond-line treatmentKaplan-Meier methodFollow-up timeSubgroup survival analysisCox proportional hazards modelsComprehensive clinical dataMulti-center studyProportional hazards modelFrontline therapyNodal involvementResponding patientsT-PLLAsparaginase Treatment Patterns, Toxicity, and Outcomes Among Patients with Extranodal NK/T-Cell Lymphoma: A North American Multicenter Retrospective Cohort Study
Allen P, Bagley E, Graf K, Sethi T, Foss F, Dong N, Saeed H, Wang J, Dittus C, Paulino D, Wilcox R, Barta S, Carvajal V, Mehta-Shah N, Mou E, Ravindra A, Haverkos B, Mehta A, Shea L, Zain J, Reef D, Ayzman A, Greenwell I. Asparaginase Treatment Patterns, Toxicity, and Outcomes Among Patients with Extranodal NK/T-Cell Lymphoma: A North American Multicenter Retrospective Cohort Study. Blood 2024, 144: 1690. DOI: 10.1182/blood-2024-211424.Peer-Reviewed Original ResearchExtranodal NK/T-cell lymphomaNK/T-cell lymphomaAsparaginase useENKTL patientsResponse rateTreatment patternsDiscontinued due to toxicityMulticenter retrospective cohort studyNon-ASP groupAssociated with significant ratesTherapy related deathsEBV-associated lymphomasKaplan-Meier methodCox proportional hazards regressionRetrospective cohort studyQuarter of patientsProportional hazards regressionStatistically significant advantageHigh response rateLimitations of therapyAnalysis of outcomesAssociated lymphomaChemotherapy backboneNeutropenic feverAsparaginase doses
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply